CLChristian Lampl

Christian Lampl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Lampl has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EMHA migraine scoring system: A novel, valid, and reliable metric to capture severity, align with patients, and facilitate communication

    by Patricia Pozo-Rosich, Edoardo Caronna, Elena Ruiz De La Torre, Messoud Ashina, Pablo Irimia, Antoinette MaassenVanDenBrink, Dimos D. Mitsikostas, Christian Lampl, Raquel Gil-Gouveia, Faisal Mohammad Amin, et al.

    Background: Available instruments to quantify migraine-related disability, such as the Headache Impact Test (HIT-6) and Migraine Disability Assessment Test (MIDAS), have certain limitations (e.g., recall bias, overlooking interictal burden), and do not always facilitate patient-doctor communication. We developed a migraine scoring system, namely the European Migraine and Headache Alliance–Migraine Scoring System (EMHA-MSS) with the aim of improving patient communication with healthcare professionals. Methods: Cross-sectional, descriptive, quantitative study conducted between June 2024 and March 2025. First, we used exhaustive diary registries from 319 Spanish-speaking patients for a pilot study (of whom n = 280 had complete HIT-6/MIDAS). Second, the EMHA-MSS was administered to a validation cohort of Spanish patients ( N = 504). Third, we undertook cross-language analyses using a separate English-language dataset from English-speaking patients ( N = 51). The pilot benchmarking analyses used an exploratory three-item version of the scale with different scoring, whereas the final psychometric analyses used the four-item EMHA-MSS. Results: The EMHA-MSS demonstrated unidimensional structure with excellent Confirmatory Factor Analysis fit (Comparative Fit Index = 1.000, Tucker-Lewis Index = 1.000, Root Mean Square Error of Approximation = 0.000, Standardized Root Mean Residual = 0.003). Acute treatment reliability was identified as the main factor driving reclassification between severity categories when comparing EMHA-MSS and HIT-6 or MIDAS (comparisons used an exploratory 3-item EMHA-MSS with different scoring in the pilot cohort). Our model provided an excellent fit, supported the expected factorial structure, and demonstrated that factor scores could be reliably calculated. The EMHA-MSS showed good to excellent test-retest reliability. Cross-language validity was demonstrated for the English version using configural and metric invariance, as well as partial scalar invariance. Conclusion: The EMHA-MSS highlighted the importance of treatment reliability, pain and attack intensity, and frequency in classifying patients with migraine and evaluating the severity of the disease. This novel scoring system could facilitate tailored management and monitoring of migraine over time, potentially improving alignment with patients’ perceptions and enhancing the understanding between them and healthcare providers.

  • Open Access

    Interictal burden in migraine: a systematic review of conceptual domains and measurement properties of instruments

    by Cornelius Angerhöfer, Yutaro Fuse, Samuel Van Langenhove, Thomas Canning, Alice C. von Alvensleben, Sheharyar Ahmad, Ane Murillo, Laia Boada, Maria M. Roque, Antoinette MaassenVanDenBrink, et al.

    Background: Migraine imposes significant burden not only during acute attacks but also during headache-free interictal periods. Several patient-reported outcome measures (PROMs) have been used to assess this interictal burden, yet the quality of their measurement properties has not been systematically evaluated. Objectives: To identify instruments used to assess interictal burden in migraine, evaluate their measurement properties using the COSMIN methodology, and synthesize the conceptual domains of interictal burden. Methods: A systematic search of MEDLINE, Embase, PsycINFO, CINAHL, and Web of Science Core Collection was conducted from database inception to 20 February 2026. Studies evaluating measurement properties of PROMs assessing interictal burden or migraine impact in migraine populations were eligible. The COSMIN risk-of-bias checklist and criteria for good measurement properties were applied. Findings were synthesized in accordance with PRISMA 2020. Results: Among 29 included studies, three instruments were identified: the Migraine Interictal Burden Scale-4 (MIBS-4; 26 studies), the Eurolight questionnaire (1 study), and the Fear of Attacks Inventory (FAMI; 2 studies). Seven conceptual domains of interictal burden were identified: functional impairment, social and relational impact, psychological and emotional distress, cognitive dysfunction, sensory symptoms, physical symptoms, and behavioral modifications. Evidence of measurement properties was concentrated in construct validity (19 studies) and responsiveness (8 studies). Structural validity, internal consistency, test–retest reliability and content validity were sparsely evaluated. The MIBS-4 demonstrated consistent convergent and known-groups validity and sensitivity to change across preventive therapies, including CGRP-targeted treatments and onabotulinumtoxinA. Conclusions: The MIBS-4 is the most widely used instrument for assessing interictal burden. Despite encouraging evidence of construct validity and responsiveness, comprehensive psychometric studies addressing content and structural validity, reliability, and measurement error, alongside conceptual work towards broader interictal burden assessment, are needed. Registration: PROSPERO CRD420261296323; Clinical trial number : not applicable.


  • Open Access

    Evaluating the relationship between the 4-item migraine interictal burden scale and other patient-reported outcome measures: a post hoc analysis from a phase 3 migraine prevention study

    by Christian Lampl, Richard B. Lipton, Sarah Lipsius, Janet H. Ford, Grazia Dell’AGnello, Lars Viktrup, Dawn C. Buse

    Background: People with migraine report reduced health-related quality of life during ictal and interictal phases. However, most patient-reported outcome measures (PROMs) focus on impact during migraine episodes (ictal) or globally (both ictal and interictal), potentially neglecting interictal burden. This exploratory analysis evaluated correlations between the 4-item Migraine Interictal Burden Scale (MIBS-4) total score and other PROMs in people with migraine. Methods: A post hoc analysis was conducted using participant data from a galcanezumab phase 3, placebo-controlled, 3-month study, followed by a 3-month open-label extension in participants with prior treatment failures. Correlations were assessed between baseline MIBS-4 and disease characteristics, baseline MIBS-4 and demographics, and MIBS-4 and other PROMs/monthly migraine headache days at baseline and at Month (M) 6, using Spearman’s rank correlation coefficient (r s ). Results: A total of 462 participants were included (mean age: 45.8 years); 85.9% were female, 58.2% had episodic migraine and 41.8% had chronic migraine. At baseline, highest correlations with MIBS-4 were observed for Migraine Specific Quality of Life Questionnaire (MSQ)-total score, MSQ-Emotional Function (MSQ-EF), and the Patient Health Questionnaire (PHQ-9) score, which measures depressive symptoms (all p < 0.001). Correlation analysis between MIBS-4 and MSQ-total score revealed moderate correlation at baseline ( r s :–0.53) that transitioned to moderate-high at M6 ( r s :–0.70). MIBS-4 was moderately correlated with PHQ-9 score at baseline ( r s :0.55) and M6 ( r s :0.55). The Migraine Disability Assessment score transitioned from moderate-low correlation at baseline ( r s :0.41) to moderate at M6 ( r s : 0.53) and Generalized Anxiety Disorder score had moderate-low correlation at both time points ( r s :0.42–0.47). MIBS-4 had moderate-negligible correlation with monthly migraine headache days at baseline ( r s :0.21) and low correlation at Month 6 ( r s :0.32). Conclusion: Interictal burden, as assessed by MIBS-4, was moderately correlated with PROMs like MSQ, PHQ-9, and MIDAS, but moderate-negligible to low correlation was observed with monthly migraine headache days. These results indicate that interictal burden is a unique construct that is correlated with, but not fully captured by, other measures and should be considered when managing people with migraine. Clinical trial registration: ClinicalTrials.gov identifier NCT03559257.


  • Open Access

    Diagnostic tests and headache misdiagnoses in individuals with resistant and refractory migraine – data from the REFINE study

    by Federico De Santis, Chiara Rosignoli, Agnese Onofri, Mark Braschinsky, Olga Sved, Raquel Gil-Gouveia, Renato Oliveira, Christian Lampl, Jakob Paungarttner, Paolo Martelletti, et al.

    Background: Individuals with difficult-to-treat migraine, including resistant migraine (ResM) and refractory migraine (RefM), might experience treatment delays, undergo unnecessary diagnostic tests and receive misdiagnoses, which might influence treatment outcomes. For this reason, we hypothesized that individuals with ResM and RefM might report more diagnostic tests and misdiagnoses in their medical history compared with those with non-resistant/non-refractory migraine (NRNRM). Methods: This analysis used baseline, cross-sectional data from the REFINE study, a multicenter, prospective observational study conducted in 15 European tertiary headache centers. Adults with episodic or chronic migraine were classified into RefM, ResM, or NRNRM groups. Baseline data were analyzed to assess the frequency of previous diagnostic tests and misdiagnoses. Results: Overall, 689 participants were included with a median age of 46 years (interquartile range 36–53); 570 participants (82.7%) were female; 355 (51.5%) had NRNRM, 261 (37.9%) ResM, and 73 (10.9%) RefM. Referring to diagnostic tests, 335 participants (48.7%) had one and 237 (34.4%) multiple brain magnetic resonance imaging scans. ResM and RefM participants underwent more diagnostic tests than NRNRM. Overall, 193 participants (28.0%) had at least one prior headache misdiagnosis, most commonly cervical spine disorders and sinusitis; misdiagnoses were more frequent in NRNRM and ResM than in RefM (31.1%, 28.5%, and 15.1%, respectively; p = 0.025). Misdiagnosis rates were not influenced by age, sex, disease duration, or comorbidities. Conclusions: Diagnostic tests use and misdiagnoses are highly prevalent in all the three groups of individuals with ResM, RefM, and NRNRM with some differences across the three groups that may depend on multiple factors. Our findings emphasize a need for better diagnostic accuracy and care pathway across the entire spectrum of migraine, to avoid unnecessary diagnostic tests and misdiagnoses.

  • Open Access

    Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond

    by Damiana Scuteri, Michalis Kodounis, Masahito Katsuki, Burcu Bezgal, Natalia Bednarczyk, Savvas Konstantinos Alevetsovitis, Justyna Wołos, Mariana Henriques, Teresa Ascensão Pinheiro, Antoinette MaassenVanDenBrink, et al.

    Migraine is the fourth leading cause of disability worldwide. It impairs patients’ physical, emotional and social functioning, as well as their produ


  • Open Access

    Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry‐Based Real‐World Study

    by Christian Lampl, Reem Suliman, Viktoria Tischler‐Strasser, Antoinette MaassenVanDenBrink, Taoufik Alsaadi

    Background: Recent post‐marketing studies have indicated a possible association between anti‐CGRP receptor monoclonal antibodies (anti‐CGRP‐mAbs) used for migraine prophylaxis and an increased risk of hypertension (HT). Methods: We performed a retrospective real‐world exploratory study, including individuals with a confirmed diagnosis of migraine who were treated with erenumab, an anti‐CGRP receptor (r)‐mAb, for at least 12 months. Inclusion was limited to individuals with complete clinical records and regular follow‐up, with at least one visit every 3 months and data available to assess treatment outcomes. Patients were excluded if they had previously received anti‐CGRP mAbs or gepants for migraine prevention before starting the current therapy, were on any concomitant baseline migraine preventive treatment, or did not complete the 12‐month follow‐up visits. Results: One hundred twenty‐five participants were eligible and included in the analysis. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were compared between baseline and follow‐up visits, conducted every 3 months for up to 24 months while the patient was on treatment. Individuals treated with erenumab initially received 70 mg, administered subcutaneously every 4 weeks. Throughout the 12‐month treatment period, blood pressure (BP) measurements remained stable and within normal physiological ranges, indicating no significant hypertensive effect. Analysis across multiple visits showed that SBP ranged from 118 to 121 mmHg, while DBP stayed between 78 and 80 mmHg. Erenumab treatment over 24 months in 54 patients demonstrated stable BP with no notable hypertensive effects. Conclusions: This study did not find sufficient evidence that treatment with erenumab leads to the development of HT.


  • Open Access

    Migraine stigma and general knowledge of migraine: A cross-sectional European survey

    by Peter J. Goadsby, Elena Ruiz de la Torre, Antoinette Maassen van Den Brink, Pablo Irimia, Dimos D. Mitsikostas, Messoud Ashina, Gisela M. Terwindt, David Hurtado, Christian Lampl, Patricia Pozo-Rosich

    Background: The stigma associated with migraine impacts patients’ quality of life, mental health and their willingness to seek treatment. The present study aimed to gain insights into the stigma from the patient's perspective and to assess migraine knowledge among people without the condition. Methods: This cross-sectional descriptive, quantitative study used two surveys (survey 1, open April 2023 to July 2023; survey 2, September 2023 to November 2023). The surveys were distributed to local patient organisations across 26 European countries and nine countries in South and North America, Asia and Oceania. Results: Survey 1 received 3712 answers. Most respondents were women (3444; 92.8%), 45–54 years (1090; 29.4%) and experienced severe migraine (2047; 55.1%). Most participants viewed their migraine as disabling (2655; 71.5%) and felt that medical professionals only partially understood (2135; 57.5%). Survey 2 gathered 774 responses, with most of the participants being partners (202; 26.1%), friends (196; 25.3%) or other relatives (110; 14.2%) of individuals with migraine. The significant majority of respondents demonstrated a high understanding of migraine (573; 74.0%) and predominantly recognised migraine as disabling and impacting personal and professional life. Responders felt a high degree of stigma, more from work colleagues and medical professionals than from their social network. Conclusions: The disabling nature of migraine, combined with the associated stigma, aggravates the challenges faced by patients. There is an urgent need for improved medical education, public awareness campaigns and possible revisions in medical terminology to better support people with migraine and mitigate the stigma they encounter. Importantly, medical professionals need to re-double efforts to check their behaviour to avoid adding to the burden of our patients.


  • Open Access

    What does a migraine aura look like?—A systematic review

    by Ľubica Joppeková, Maria João Pinto, Mariana Dias da Costa, Richard Boček, Gabriele Berman, Yones Salim, Dinara Akhtanova, Aizhana Abzalbekova, Antoinette MaassenVanDenBrink, Christian Lampl, et al.

    Migraine with aura is a prevalent neurological disorder that affects up to 30% of individuals experiencing migraines. It presents as temporary neurological disturbances, primarily visual, but also includes sensory, speech, motor, and brainstem symptoms. The underlying pathophysiology is closely tied to cortical spreading depression, which initiates neurovascular and inflammatory changes. Epidemiological studies show significant variations in the prevalence of migraine with aura across different demographics, with a more pronounced effect observed among women. Genetic research has identified both common and rare variants that influence susceptibility to migraine with aura, with genome-wide association studies revealing distinct risk loci. Neuroimaging studies indicate structural and functional alterations in cortical and subcortical areas, reinforcing the role of altered brain connectivity in migraine with aura. Additional studies, including various neurophysiological techniques (such as EEG, VEP, or TMS), are needed to potentially identify specific patterns within MA that would help better characterise clinical and electrophysiological phenotypes. Differential diagnosis is essential, as migraine aura symptoms may overlap with a wide range of primarily neurological paroxysmal disorders. While the treatment of migraine traditionally prioritises the headache, there is limited evidence for targeted therapies addressing aura symptoms; further research is warranted. This systematic review offers a comprehensive synthesis of aura types, epidemiology, genetics, pathophysiology, diagnosis, and management of migraine with aura, emphasising areas for future exploration.


  • Top Cited Papers
    Open Access

    Migraine with and without aura—two distinct entities? A narrative review

    by Olga Grodzka, Ketevan Dzagoevi, Tayla Rees, Goncalo Cabral, Piotr Chądzyński, Stefano Di Antonio, Patryk Sochań, Antoinette MaassenVanDenBrink, Christian Lampl, on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)

    Migraine is a primary headache disorder, with a prevalence estimated at approximately 15% globally. According to the International Classification of Headache Disorders, 3rd edition (ICHD3), there are three significant types of migraine: migraine without aura (MO), migraine with aura (MA), and chronic migraine (CM), the former being the most common. Migraine diagnosis is based on official criteria specific to each type. Although a lot is already known about the origin of migraine aura, its pathophysiology is still an object of research. Long-term discussions have been held about MO and MA, with some evidence for the same underlying pathogenesis of both and other arguments against it. In this narrative review, we decided to analyse multiple factors from the perspective of similarities and differences between these two types of migraine. The aim was to understand better the bases underlying both types of migraine. Aspects such as genetics, molecular bases, relation with hormones, epidemiological and clinical features, neuroimaging, neurophysiology, treatment response, and migraine complications are covered to find similarities and differences between MO and MA. Although epidemiology shares similarities for both types, there are slight alterations in sex and age distribution. Genetics and pathogenesis showed some crucial differences. Conditions, such as vestibular symptoms and depression, were found to correlate similarly with both types of migraine. For some features, including increased cardiovascular risk, the tendency appeared to be the same; however, migraine types differ in the strength of correlation. Finally, in cases such as hormones, the influence has shown opposite directions. Therefore, although migraine with and without aura are considered two types of the same disease, more research should focus on their differences, thus finally enabling better specific treatment options for both types of migraine.


  • Open Access

    Effects of proton pump inhibitor (PPI) use on migraine – a critical review

    by Viktoria Tischler-Strasser, Irma Burdiladze, Goncalo Cabral, Esme Ekizoglu, Olga Grodzka, Keshet Pardo, Patryk Sochan, Laura Zaunandra, Antoinette MaassenVanDenBrink, Christian Lampl, et al.

    Proton pump inhibitor (PPI) drugs are widely used and are among the most significant achievements of modern pharmacology. Their primary purpose is treating and preventing gastric acid-related disorders. Migraine and PPI intake are prevalent, and many people are affected by both. In the last few years, a potential link between PPI intake and the development of headaches—especially migraine–has come to increased attention. In this review, we critically examine the scientific data concerning the co-occurrence of these two entities. There seems to be a possible link between the use of PPIs and the occurrence of headache, especially migraine, suggesting a pathophysiological connection on several levels. Moreover, PPI use is only partially without side effects, even if these may not occur immediately. Whether the relation is causative or merely co-existential is currently not yet clear. The influence of genetics, environment, gut microbiome, medication intake and evolution of headache is multidirectional. A relation between the prevalence of migraine and the use of PPIs on a population and personal level seems likely. Although PPIs have many advantages, they should be prescribed with caution, especially in patients who suffer from headaches and migraine. In this narrative review, we aim to critically evaluate existing data and offer a potential approach to accurately identify any connections and interactions, leading to a better understanding of how these conditions may influence each other.